




GeneNavTM HPV Genotyping qPCR Kit

IVD (E

REF E115

Introduction

Over 130 HPV types have been documented in literature, approximately 40 of which infect the anogenital area and are sexually transmitted. Persistent anogenital high risk HPV infection is associated with the majority of cervical cancers. Cervical cancer has previously been shown to be highly preventable when cytological and HPV screening programs are employed to facilitate early detection and treatment of pre-cancerous lesions. Of the sexually transmitted HPV genotypes, 14 (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) are considered high risk and commonly lead to cervical cancers. The GeneNavTM HPV Genotyping qPCR Kit utilizes quantitative PCR (qPCR) technology to specifically detect and simultaneously genotype each of these 14 high risk HPV types in an eight-tube assay.



Kit Components

PN Part Number	Kit Components	Quantity	
E-1G	Diagnostic 2X qPCR MasterMix - No Dye	2 x 1 ml	
E115-XA	GeneNav [™] HPV Genotyping Primers X	25 μΙ	
E115-XB	GeneNav [™] HPV Genotyping Probes X	25 μΙ	
E5	Sample Prep Solution	5 ml	
E0	Nuclease-free Water	2 x 1 ml	

- For 24 preps
- X = Number from 1 to 8, a total of 8 primers and 8 probes
- Store all reagents between -25°C to -15°C in a non-frost-free freezer



Detailed Protocol

Principles of the Assay

The GeneNav[™]HPV Genotyping qPCR Kit uses probe-based qPCR technology to detect HPV with high specificity. Each sequence-specific probe contains a 5' fluorophore and a 3' quencher. On its own, the probe's 3' quencher effectively absorbs the emission from the nearby 5' fluorophore so that no net fluorescence is detected. During PCR amplification, the probe binds to its specific target template. While replicating the DNA sample, the PCR Taq Polymerase's 5' to 3' exonuclease activity also hydrolyzes the probe, releasing a free-floating 5' fluorophore that is detectable by the qPCR machine and can be translated into an amplification plot. In this HPV Genotyping qPCR kit, the 14 types of high risk HPV and a human ACTIN control are divided into 8 reaction tubes, with 2 fluorescent channels per tube: FAM and HEX. Detection of a positive signal in a particular channel can identify a specific genotype of HPV. An internal control, human ACTIN, indicates the quality of extracted DNA.

Sample Requirements

Specimens are limited to cervical cells collected through a cervical swab. For the GeneNav[™] HPV Genotyping qPCR Kit, cervical specimens can be stored in the Specimen Transportation Medium for up to 3 days (between 2 to 8°C) or up to 6 months (at -20°C) prior to testing. Avoid repeated freeze/thawing of the samples.

DNA Isolation

- 1. Transfer 500 μ l of freshly re-suspended Specimen Transport Media/Sample mixture into an Eppendorf tube. Centrifuge the mixture at 12000 rpm for 5 minutes. Discard the supernatant.
- 2. Thoroughly re-suspend the Sample Prep Solution (E5) and immediately transfer 200 μ l of the freshly re-suspended Sample Prep Solution (E5) to the collected cell pellet.
- 3. Vortex the mixture thoroughly. Heat the mixture at 100°C for 10 minutes then cool the mixture on ice for 5 minutes. Centrifuge the mixture at 12000 rpm for 5 minutes. The resulting supernatant is used directly as the template in the
- 4. ensuing analyses and will be referred to as the "extracted DNA".

note

If the supernatant is transferred into another tube, it may be stored up to one year at -20°C.

Quantitative PCR (qPCR) Reaction Setup

- Thaw the following reagents on ice: Diagnostic 2X qPCR MasterMix No Dye (E-1G), the eight GeneNav™
 HPV Genotyping Primers X (E115-XA), and the eight GeneNav™ HPV Genotyping Probes X (E115-XB).
 Gently and evenly mix each individual reagent, then briefly centrifuge the reagents to collect the contents.
- 2. A premix solution is needed for each of the eight reaction tubes (i.e. Premix *X* for tube *X*). Each premix solution should contain the corresponding primers and probes for tube *X*. Each premix *X* volume = (number of sample preps + 1) x the total volume of premix reagents for tube *X* as listed below:

Reagents for Premix X	Volume
Diagnostic 2X qPCR MasterMix - No Dye (E-1G)	10 μΙ
GeneNav [™] HPV Genotyping Primers X (E115-XA)	1 μΙ
GeneNav [™] HPV Genotyping Probes X (E115-XB)	1 μΙ
Nuclease-free Water (E0)	6 μΙ
Total Volume	18 µ l
V. Noveley from 4 to 0 - total of 0 and	

X ⇒ Number from 1 to 8, a total of 8 primers and 8 probes

Figure 1: 96-well qPCR Setup Guide. You may adjust this setup to suit your own needs.

Premix 1	1	2	3	4	5	6	7	8	9	10	11	NTC	
Premix 2	1	2	3	4	5	6	7	8	9	10	11	NTC	
Premix 3	1	2	3	4	5	6	7	8	9	10	11	NTC	
Premix 4	1	2	3	4	5	6	7	8	9	10	11	NTC	
Premix 5	1	2	3	4	5	6	7	8	9	10	11	NTC	
Premix 6	1	2	3	4	5	6	7	8	9	10	11	NTC	
Premix 7	1	2	3	4	5	6	7	8	9	10	11	NTC	
Premix 8	1	2	3	4	5	6	7	8	9	10	11	NTC	

- 3. Please refer to **Figure 1** as a guide for this step. Evenly aliquot each premix into its corresponding qPCR tube labelled Premix 1 to 8. Add 2 μ l of each extracted DNA solution (refer to Step 4 of DNA Isolation protocol) into all eight qPCR tubes. Do not add more than one sample of extracted DNA into a single qPCR tube.
- 4. Use Nuclease-free Water (E0) instead of extracted DNA for the No Target Control (NTC). A single 96-well qPCR plate can run 11 patient samples and 1 NTC, as shown in **Figure 1**.

Control: The NTC must be run on each assay plate, and the cycle threshold (CT) for NTC must be more than 35 for the samples on the plate to be valid. If this criteria is not met, the samples and controls on that plate are invalid and must be repeated.

qPCR Cycling Condition

Transfer the reaction setup into a qPCR machine and set up the following thermal cycling program. It is recommended to use Applied Biosystem's 7500, QuantStudio's 7 Flex system, or BioRad's CFX96 instrument.

DNA Pre-denaturing	95°C, 10 min	1 Cycle	
Denaturing	95°C, 15 sec	40 Cycles	
Anneal / Extension	61°C, 60 sec (Collect FAM and HEX signals)		



Signals are collected at the end of each extension step through FAM and HEX channels.

Detection Channels

Two detection channels (FAM and HEX) are used in each of the eight tubes. It is recommended to perform the color (channel) calibration as requested by the instrument's manufacturer. Please refer to the instrument's user manual to perform this calibration. Choose the FAM and HEX channels for all 8 tubes containing samples to be tested with GenomeMeTM's GeneNavTM HPV Genotyping qPCR Kit.

Result Analysis

- 1. If the internal control channel (FAM in Tube 8) shows a CT value of greater than 37, the test has failed due to insufficient amounts of DNA or poor quality DNA. Re-extract DNA and repeat the assay.
- 2. If the internal control shows a CT value of less than 37, and all other HPV types (FAM and HEX in Tubes 1 to 7) show a CT value of greater than 37, the sample is negative for all 14 types of HPV that this kit detects.
- 3. If both the internal control (FAM in Tube 8) and any one of the HPV types (FAM or HEX in Tubes 1 to 7) show a CT value of less than 37, the sample is positive for the indicated HPV type.
- 4. If the internal control (FAM in Tube 8) and two or more of the HPV types (FAM or HEX in Tubes 1 to 7) show a CT value of less than 37, the sample is positive for all indicated HPV types (Chimeric Infection).

Refer to the table below for HPV genotyping information per tube and channel.

Tube #	Channel H	PV Type	Tube #	Channel HPV Type		
Tube 1	FAM	16	Tube 5	FAM	52	
	HEX	68		HEX	39	
Tube 2	FAM	18	Tube 6	FAM	33	
	HEX	35		HEX	51	
Tube 3	FAM	31	Tube 7	FAM	59	
	HEX	66		HEX	56	
Tube 4	FAM	58	Tube 8	FAM	Internal Control	
	HEX	45				

note

Sample results are only valid when negative controls yield no amplification. If the NTC is invalid in an assay, all sample results in the same assay are therefore also invalid and the assay must be repeated.

Performance Characteristics

The following performance characteristics of the GeneNav™ HPV Genotyping qPCR Kit have been established following the procedure described in this datasheet.

Analytical Sensitivity: 130 copies/reaction for all 14 types

Analytical Specificity: Cross reaction among these 14 HPV types was not observed. A panel of bacteria, fungi, and viruses commonly found in the female anogenital tract were tested with the GeneNav[™] HPV Genotyping qPCR Kit to assess potential cross-reactivity. The pathogens tested include: Candida albicans, Proteus vulgaris, Corynebacterium pseudodiptheriticum, Staphylococcus aureus, Enterococcus faecalis, Staphylococcus epidermidis, Escherichia coli, Streptococcus mitis, Lactobacillus acidophilus, Streptococcus pyogenes, Herpes simplex virus, type 1 and 2 (HSV-1 and 2), Chlamydia trachomatis, Neisseria gonorrhoeae, Human Immunodeficiency Virus type 1 (HIV-1 pol and env regions), and Mycoplasma hominis. Negative results were obtained from all above-mentioned organisms.

Reproducibility: Reproducibility of the GeneNav™ HPV Genotyping qPCR Kit was assessed at two external sites using a panel of HPV positive and negative cultured cells and HPV positive and negative cervical specimens. DNA was extracted from 500 µl of cervical samples or cultured cells suspended in Specimen Transportation Medium. The DNA was extracted using the sample prep solution included in this Kit. DNA was extracted from sixteen samples and tested with GeneNav™ HPV Genotyping qPCR Kit at two sites on five non-consecutive days within a two-week time period. Two lots of GeneNavTM HPV Genotyping qPCR Kits were used across the two sites for the study. The total number of measurements for each sample was 20 (2 sites x 5 days x 2 lots x 1 run per day). The results showed that the coefficient of variation (CV) for the kit performance was less than 5% among different product lots and different operators.

Limitations

- 1. The GeneNav™ HPV Genotyping qPCR Kit detects DNA of 14 HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
- 2. A negative result does not exclude the possibility of HPV infection because very low levels of infection or sampling error may cause a false-negative result.

 3. The test has been validated for use only with cervical swab specimens collected in specimen transportation medium.
- The performance of the GeneNav™ HPV Genotyping qPCR Kit was established exclusively using DNA extracted with the enclosed sample prep solution.
- 5. The performance of the GeneNavTM HPV Genotyping qPCR Kit has not been adequately established for HPV vaccinated individuals.
- 6. Prevalence of HPV infection in a population may affect performance. Positive predictive values decrease when testing populations with low prevalence or individuals with no risk of
- 7. Infection with HPV is not an indicator of cytologic High-grade squamous intraepithelial lesion (HSIL) or underlying high-grade Cervical intraepithelial neoplasia (CIN), nor does it imply that CIN2-3 or cancer will develop. Most women infected with one or more HPV types do not develop CIN2-3 or cancer.
- 8. A negative High-Risk HPV result does not exclude the possibility of future cytologic HSIL or underlying CIN2-3 or cancer.

Disclaimer

INTENDED USE:

- 1. To diagnose and identify the exact type of HPV infection in patients. Detection of HPV using the GeneNav™ HPV Genotyping qPCR Kit can differentiate between HPV types and evaluate persistence of one type.
- 2. In women 30 years and older, the GeneNav™ HPV Genotyping qPCR Kit can be used with a cervical cytology to adjunctively assess the presence or absence of HPV infection. This information, together with the physician's assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management.

WARNINGS:

- 1. The GeneNav™ HPV Genotyping qPCR Kit is not intended for use as a screening device for women under age 30 with normal cervical cytology.

 2. The GeneNav™ HPV Genotyping qPCR Kit is not intended to substitute for regular cervical cytology screening.

 3. The use of this test has not been evaluated for the management of women with prior cytological or histological abnormalities, have had a hysterectomy, who are pregnant, postmenopausal, or who have other risk factors (e.g., HIV+, immunocompromised, history of STI).

 4. The GeneNav™ HPV Genotyping qPCR Kit is designed to enhance existing methods for the detection of cervical disease and should be used in conjunction with clinical
- information derived from other diagnostic and screening tests, physical examinations, and full medical history in accordance with appropriate patient management procedures.
- 5. The GeneNav™ HPV Genotyping qPCR Kit results should not be used as the sole basis for clinical assessment and treatment of patients.

NOTICETO RECIPIENT ABOUT LIMITED LICENSE:
The receipt of product from GenomeMe™, or its authorized distributor, includes a limited, non-exclusive, nontransferable license under certain intellectual property rights held by GenomeMeTM. This license is only for the purpose of using the product in the methods for which they were intended. This limited license does not include a license to use the product for new product research or development, product manufacture, reverse engineering improvements to the product technology or any other commercial purpose. The Customer is not authorized to transfer this product to any third party for any purpose whatsoever without the express written consent of GenomeMe™. Except as otherwise stated in this paragraph, no other license is granted expressly, impliedly or by estoppel. For information concerning the availability of additional licenses to practice the patented methodologies, contact: Legal Department, GenomeMe™ Inc., 1-3691 Viking Way, Richmond, BC, V6V 2J6, Canada.

LIMITED PRODUCT WARRANTY

WARRANTIES. The product is warranted to the original Customer to perform substantially in accordance with published Product Specifications for one (1) year starting from the date of Delivery. Consumables are warranted to conform to published specifications for a period ending on the expiration date shown on the respective packages. GenomeMeTM does not warrant that use of products will be uninterrupted or error-free, or that products will operate with non-GenomeMeTM authorized third-party products. GenomeMeTM's entire warranty responsibility is expressly limited to the replacement of product or, at GenomeMeTM's discretion, repayment of, or crediting Customer with, an amount equal to the GenomeMeTM price, fee or charge therefore. The foregoing warranties are in lieu of and exclude all other warranties not expressly set forth herein, whether expressed or implied by operation of law or

otherwise, including but not limited to any implied warranties of merchantability or fitness for a particular purpose. Such limited warranty is given solely to the original Customer and is not given to, nor may it be relied upon by, any third party including, without limitation, customers of the Customer. This warranty is void upon transfer of product by customer to any entity with less than fifty (50) percent ownership in the product. Some states do not allow the exclusion of implied warranties so the above exclusions may not apply to you. You may also have other rights, which vary from state to state. These warranties do not apply to any item that is: (a) altered other than by GenomeMeTM authorized service personnel; (b) aso have other highs, which vary home state to state. These warrantes do not apply or any hern that is, (a) aftered other high by GenomeNet[™] authorized service personnel subjected to physical (including thermal or electrical) abuse, stress, or misuse; (c) stored, maintained or operated in any manner inconsistent with applicable GenomeMe[™] specifications or instructions; or (d) designated as supplied subject to a non-GenomeMe[™] warranty or on a pre-release or "as-is" basis.

WARRANTY CLAIMS AND REMEDIES:

In the event of any warranty claim, GenomeMe™ will replace the product with a new product. Alternatively, GenomeMe™ may elect to repay or credit to the Customer an amount equal to the purchase price of the defective product. Items replaced shall become GenomeMeTM property. All claims shall be initiated by contacting GenomeMeTM within the applicable warranty period and thirty (30) days after discovery of the breach or non-conformity. GenomeMeTM must be given reasonable access and an opportunity to inspect all associated materials. If GenomeMe™ and the Customer are unable to settle any claim and the Customer has not notified GenomeMe™ within one (1) year after the claim arises, the Customer shall be barred from instituting any legal action thereafter. These remedies shall comprise GenomeMeTM's entire liability and Customer's exclusive remedy for breach of warranty and are in lieu of any other remedies at law or equity.

GenomeMe™ shall not be liable for any special, incidental, punitive, exemplary or consequential losses, damages, or expenses (including but not limited to loss of profits, data, or derinterior—stall not be labeled if any special, including, puritive, exemplarly of consequential issess, damages, or expenses (including but not inflied to loss of profits, data, or use), directly or indirectly arising from the sale, handling, service or use of product ordered or furnished, or from any cause relating thereto unless expressly agreed to by the parties in writing. Except for personal injury or death to the extent resulting from GenomeMe™s negligent or intentionally wrongful acts or omissions, in no event shall GenomeMe™ be liable under any legal theory or for any cause whatsoever, whether based upon warranty, contract, tort, negligence, or other theory, even if advised of the possibility thereof, for any amount in excess of the price, fee or charge therefore received by GenomeMe™.

GenomeMe™ and GeneNav™ are registered trademarks of GenomeMe™ Inc. and/or its subsidiaries in Canada and/or other countries. All other trademarks that may appear in this datasheet are the property of their respective owners. Some components of nucleic acid analysis, such as specific methods and compositions for manipulating or visualizing nucleic acids for analysis, may be covered by one or more patents owned by other parties. Similarly, nucleic acids containing specific nucleotide sequences may be patented. Making, using or selling such components or nucleic acids may require one or more licenses. Nothing in this document should be construed as an authorization or implicit license to make, use or sell any so covered component or nucleic acid under any such patents.